Effects of Anti-Tuberculosis Drugs on Lipid Profile in Pulmonary Tuberculosis Patients

Authors

  • Nisar Ahmed Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
  • Iqra Amjad Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
  • Zain Abbas Malik Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
  • Abdullah Naseer Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
  • Mubashir Raza Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
  • Aqsa Imtiaz Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
  • Hina Awais Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
  • Talha Mannan Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
  • Adeel Ahmad Department of Microbiology, University of Health Sciences, Lahore, Pakistan.

DOI:

https://doi.org/10.36570/jduhs.2022.2.1235

Keywords:

Tuberculosis, Drug-induced hepatotoxicity, Total Cholesterol, Triglycerides, High-density lipoprotein, Low-density lipoprotein, low-density lipoprotein

Abstract

Objective: To determine the anti-tuberculosis drugs effect on the lipid profile parameters in pulmonary tuberculosis (TB) patients.
Methods: A prospective cross-sectional study was conducted at Tehsil Headquarter Hospital, Taunsa Sharif and District Headquarter Teaching Hospital, Dera Ghazi Khan from December 2020 to May 2021. The blood samples from 84 positive pulmonary TB patients were collected in three different intervals of the study, before the start of the treatment, and after the use of first four baseline drugs isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB) respectively to check out the variation in lipid profile parameters such as total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), triglyceride (TG) and very low density lipoprotein (VLDL).
Results: Of 84 pulmonary TB patients, the mean age was 38.1 ± 19.8 years. There were 44 (52.4%) males and 40 (47.6%) females. The mean difference of cholesterol level significantly increases from baseline to 6th and 10th week, (p-value <0.001). Similarly, HDL (p-value <0.001) and LDL (p-value <0.001) also increases significantly from baseline to 6th week and 10th week. However, no significant difference of TG (p-value 0.908) and VLDL (p-value 0.367) was observed from baseline to 6th and 10th week.
Conclusion: Patients with pulmonary TB showed low lipid profile in our cohort. This shows that pulmonary TB may be a causative agent of low lipid profile. After anti-TB therapy, cholesterol, HDL, and LDL levels seem to be increased.

Downloads

Download data is not yet available.

References

Brosch R, Gordon SV, Marmiesse M, Brodin P, Buchrieser C, Eiglmeier K, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci U S A. 2002; 99(6):3684-3689.

Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med. 2005; 171(7): 699–706.

World Health Organization. Global tuberculosis control: a short update to the 2009 report. WHO/HTM/TB/2009.426. Geneva, WHO 2009; 42(39):1-9.

Falzon D, Philippe G, Ernesto J, Fuad M, Eva N, Charalambos S, et al. World Health Organization. Multidrug and extensively drug resistant TB (M/XDR-TB): global report on surveillance and response. WHO/HTM/TB 2010;8(4):16-71,

Muthraj M, Kamatchiyammal S, Usharani B, Manupriya S, Niranjana AR. Serum zinc, Calcium, and albumin levels in Pulmonary Tuberculosis co-infected with HIV. Global J Biotech Biochem. 2010;5(1):27-35.

Baddeley A, Anna D, Hannah MD, Dennis F, Katherine F, Ines GB, et al. Global Tuberculosis Report 2014. World Health Organization 2014; 2 (5): 99-145.

Hameed SP, Suresh S, Kakoli M, Vrinda N, David W, Radha S, et al. Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2014;58(1): 61-70.

Shah NS, Wright A, Bai GH, Lucia B, Fadila B, Nuria MC, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13(3):380–387.

Rieder HL, Arnadottir T, Trebucq A, Enarson A. Tuberculosis treatment: dangerous regimens? Int J Tuberc Lung Dis. 2001;5(1):1–3.

Wright A, Matteo Z, Armand Van D, Dennis F, Sabine RG, Knut F, et al. Epidemiology of antituberculosis drug resistance 2002–2007: an updated analysis of the Global Project on Anti-Tuberculosis drug Resistance Surveillance. Lancet. 2009;373(9678):1861–1873.

Gebremicae G, Yemane A, Feyissa C, Atsbeha G, Girmay M, Mistire W, et al. Lipid Profile in Tuberculosis Patients with and without Human Immunodeficiency Virus Infection. Int J Chronic Dis. 2017;2(4): 1-10.

Jeong I, Jong SP, Young JC, Ho IY, Junghan S, Choon TL, et al. Drug-induced Hepatotoxicity of Anti-tuberculosis Drugs and Their Serum. J Korean Med Sci. 2014;30(2):167-172.

Smith T, Kerstin AW, Liem N. Molecular Biology of Drug Resistance in Mycobacterium tuberculosis. Curr Trop Microbiol Immunol. 2012;1007(82):374-353.

Mirlohi MS, Alireza E, Saeed S, Mehdi G, Fatemeh P. Hematological and liver toxicity of anti-tuberculosis drugs. Electron Physician. 2016;8(9):3005-3010.

Saukkonen JJ, David LC, Robert MJ, Steven S, John AJ, Charles MN, et al. An official ATS statement: Hepatotoxicity of antituberculosis Therapy. Am Thorac Doc. 2006;174: 935-952.

Akram Y, Zahed M, Muhammad R, Irum J, Muhammad S, Tahira B, et al. Biochemical profiling of tuberculosis patients co-infected with hepatitis C viru. Eur J Inflamm. 2017;1:42-45.

Sarkar S, Advaita G, Hoon S. Current Overview of Anti-Tuberculosis Drugs: Metabolism and Toxicities. Mycobact Dis. 2016;6:1-12.

Gatfield J, Pieters J. Essential role for cholesterol in entry of mycobacteria into macrophages. Science. 2000;288:1647-51.

Sushilendu V, Kumar N, Kumar U. Study of Lipid profile in pulmonary TB cases: pre and post anti-tuberculosis treatment. J Med Sci Clinic Res. 2019;7:211-215.

Pérez-Guzmán C, Vargas MH, Quiñonez F, Bazavilvazo N, Aguilar A, Team OS. A cholesterol-rich diet accelerates bacteriologic sterilization in pulmonary tuberculosis. Chest. 2005;127: 643-651.

Taparia P, Yadav D, Koolwal S, Mishra S. Study of lipid profile in pulmonary tuberculosis patients and relapse cases in relation with disease severity-A pilot study. Indian J Sci Appl Res. 2015;2:41-50.

Downloads

Published

2022-01-27

How to Cite

Ahmed, N. ., Amjad, I. ., Abbas Malik, Z. ., Naseer, A. ., Raza, M. ., Imtiaz, A. ., Awais, H., Mannan, T. ., & Ahmad, A. . (2022). Effects of Anti-Tuberculosis Drugs on Lipid Profile in Pulmonary Tuberculosis Patients. Journal of the Dow University of Health Sciences (JDUHS), 16(2), 78–82. https://doi.org/10.36570/jduhs.2022.2.1235

Issue

Vol. 16 No. 2

Section

Original Articles

License

Copyright (c) 2022 Hina Awais

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Articles published in the Journal of Dow University of Health Sciences are distributed under the terms of the Creative Commons Attribution Non-Commercial License https://creativecommons.org/ licenses/by-nc/4.0/. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal.